Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
A phase 1/2 trial of LAM561 in glioma & glioblastoma, run by Laminar Pharmaceuticals, now recruiting.
Overview
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04299191 by Laminar Pharmaceuticals, with 28 participants planned, started 2020-09-01 and due to reach its primary completion in 2026-10. Interventions recorded: LAM561.
Similar pages
not linked directly; found by shared links- TrialLAM561 With RT and TMZ for Adults With Glioblastoma
Shares Laminar Pharmaceuticals, LAM561, Glioma & glioblastoma.
- TrialMaximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.
- TrialStudy of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Shares Glioma & glioblastoma and the tag pipeline.
- TrialInjection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.